Display options
Cite
Yoshimura K, Inui N, Karayama M, et al. Successful crizotinib monotherapy in . Respir Med Case Rep. 2017;20:160-163doi: 10.1016/j.rmcr.2017.02.009.
Yoshimura, K., Inui, N., Karayama, M., Inoue, Y., Enomoto, N., Fujisawa, T., Nakamura, Y., Takeuchi, K., Sugimura, H., & Suda, T. (2017). Successful crizotinib monotherapy in . Respiratory medicine case reports, 20160-163. https://doi.org/10.1016/j.rmcr.2017.02.009
Yoshimura, Katsuhiro, et al. "Successful crizotinib monotherapy in ." Respiratory medicine case reports vol. 20 (2017): 160-163. doi: https://doi.org/10.1016/j.rmcr.2017.02.009
Yoshimura K, Inui N, Karayama M, Inoue Y, Enomoto N, Fujisawa T, Nakamura Y, Takeuchi K, Sugimura H, Suda T. Successful crizotinib monotherapy in . Respir Med Case Rep. 2017 Feb 17;20:160-163. doi: 10.1016/j.rmcr.2017.02.009. eCollection 2017. PMID: 28271038; PMCID: PMC5322209.
Copy Download .nbib Format: NLM
Share it on

Respir Med Case Rep. 2017 Feb 17;20:160-163. doi: 10.1016/j.rmcr.2017.02.009. eCollection 2017.

Successful crizotinib monotherapy in .

Respiratory medicine case reports

Katsuhiro Yoshimura, Naoki Inui, Masato Karayama, Yusuke Inoue, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Kengo Takeuchi, Haruhiko Sugimura, Takafumi Suda

Affiliations

  1. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  2. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  3. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  4. Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
  5. Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

PMID: 28271038 PMCID: PMC5322209 DOI: 10.1016/j.rmcr.2017.02.009

[No abstract available.]

Keywords: Crizotinib; Erlotinib; MET amplification; Non-small-cell lung cancer; Resistance

References

  1. Lung Cancer. 2016 Aug;98:59-61 - PubMed
  2. Clin Cancer Res. 2013 Apr 15;19(8):2240-7 - PubMed
  3. Am J Pathol. 2001 Mar;158(3):1111-20 - PubMed
  4. Cancer Discov. 2015 Aug;5(8):850-9 - PubMed
  5. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7 - PubMed
  6. Nat Rev Cancer. 2006 Aug;6(8):637-45 - PubMed
  7. J Thorac Oncol. 2015 Nov;10(11):1590-600 - PubMed
  8. J Thorac Oncol. 2016 Jul;11(7):e83-5 - PubMed
  9. Sci Transl Med. 2011 Mar 23;3(75):75ra26 - PubMed
  10. J Thorac Oncol. 2015 May;10(5):e23-5 - PubMed
  11. Mol Cancer Ther. 2013 Dec;12(12):2817-26 - PubMed
  12. Cancer Discov. 2015 Aug;5(8):842-9 - PubMed
  13. Cancer Res. 2007 May 1;67(9):4408-17 - PubMed

Publication Types